Search

Search Constraints

You searched for: Author/Creator Robert, C

Search Results

1. 1141PDAssociation between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. (23rd October 2018)

3. 1248PDEfficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. (23rd October 2018)

4. 1250PEstimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (23rd October 2018)

5. 1251PAdverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (23rd October 2018)

6. 1260PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma. (23rd October 2018)

7. 1278PHealth-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (23rd October 2018)

8. 28TiPCHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists. (17th December 2018)

10. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. (13th August 2019)